Search - tctmd.com

Displaying 261 - 280 of 402

Sort: Relevancy | Date

News Daily News

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

Yael L. Maxwell

April 24, 2019

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

L.A. McKeown

April 03, 2019

News Daily News

Many Statin-Eligible Patients Don’t Take Meds, and Say Doctor Is to Blame

Michael O'Riordan

March 27, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Conference News ACC 2019

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

Michael O'Riordan

March 17, 2019

News Daily News

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Michael O'Riordan

March 15, 2019

News Daily News

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Michael O'Riordan

March 08, 2019

News Daily News

Quality of CAD Care Varies by Type of Medicare Coverage

Todd Neale

February 20, 2019

News Daily News

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

Michael O'Riordan

February 08, 2019

News Daily News

Bias Over Knowledge: Whether Patients Get Guideline-Recommended Statins Depends on Physician Beliefs

Yael L. Maxwell

January 10, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2018

Caitlin E. Cox

January 01, 2019

News Features

Top News in Endovascular Therapy: 2018

L.A. McKeown

December 28, 2018

News Features

Top News in Prevention: 2018

Michael O'Riordan

December 28, 2018

News Daily News

FOURIER Analysis: Evolocumab Delivers Consistent LDL Cholesterol-Lowering

Yael L. Maxwell

December 19, 2018

News Daily News

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Michael O'Riordan

December 10, 2018

News Daily News

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Michael O'Riordan

December 03, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2018

Shelley Wood

November 30, 2018

News Daily News

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

Shelley Wood

November 23, 2018

News Conference News AHA 2018

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Yael L. Maxwell

November 16, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

Advertisement

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

Many Statin-Eligible Patients Don’t Take Meds, and Say Doctor Is to Blame

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Quality of CAD Care Varies by Type of Medicare Coverage

Age Shouldn’t Be a Barrier to Statin Therapy, Meta-analysis Suggests

Bias Over Knowledge: Whether Patients Get Guideline-Recommended Statins Depends on Physician Beliefs

TCTMD’s Top 10 Most Popular Stories for December 2018

Top News in Endovascular Therapy: 2018

Top News in Prevention: 2018

FOURIER Analysis: Evolocumab Delivers Consistent LDL Cholesterol-Lowering

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

TCTMD’s Top 10 Most Popular Stories for November 2018

Certain Risk Factors Carry Higher MI Risk in Women Than in Men

EWTOPIA 75: Ezetimibe Bests Dietary Counseling Alone in Lowering Cardiovascular Risk for Elderly Japanese Patients

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content